Nutrition Table 8 Creatine Administration Post SCI

Author Year
PEDro Score
Research Design
Sample Size



Kendall et al. 2005
NInitial=9;  NFinal=8


Population: Level of injury: C5/C6; Severity of injury: AIS A-C; Time since injury=16.5 yr.
Treatment: Subjects were randomized into one of two groups receiving either 10 g creatine orally twice daily for six days, then maintained on 5 grams daily until they testing, or placebo. After a wash-out period they crossed over to the other arm.
Outcome Measures: Grasp and Release Test (GRT) and Functional Independence Measure.
  1. There were no significant between-group differences for GRT or FIM scores.

Jacobs et al. 2002
RCT (cross-over design)


Population: Mean age=35.3 yr; Gender: males=16 females=0; Level of injury: tetraplegia; Mean weight=71.4 kg.
Treatment: Individuals received 20 g of creatine monohydrate 4x/day mixed with 8 oz water or placebo powder for 1 wk. A washout period occurred for 3 wk and then individuals crossed over to receive the alternate treatment protocol.
Outcome Measures: Power output, time to fatigue, heart rate (HR), oxygen uptake (VO2), minute ventilation (VE), ventilatory frequency (VF), respiratory exchange ratio (RER), idal volume (VT).
  1. No adverse effects were reported.
  2. There was no change in HR, RER and VE, although there were significant difference in VO2, VCO2, VF and VT between trials (p<0.001).
  3. VO2 increased by 18.6% with creatine treatment versus placebo.
  4. After creatine consumption, VO2, VCO2 and VT reached their highest peak.
Effect Sizes

Note: AIS=ASIA Impairment Scale